secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001437749-26-008499
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia FDA accepts pre-submission package for Helix catheter; review meeting early Q2
--------------------------------------------------------------------------------

- FDA accepted pre-submission package for Helix Transendocardial Delivery Catheter; substantive review and meeting scheduled early Q2 2026.
- CDRH to lead review in consultation with CBER; Helix enables minimally invasive intramyocardial delivery of therapeutics/diagnostics.
- CEO states FDA marketing clearance would be meaningful for business; Helix is platform for cardiac cell, gene, and protein therapeutics.
- CardiAMP Cell Therapy Breakthrough Designation (enabled by Helix) acknowledged by FDA in this submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926008499/0001437749-26-008499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926008499/bcda20260317_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer